Arbutus Biopharma Corporation

ABUS · NASDAQ

ABUS is suddenly cash-relevant because of a Moderna/Genevant settlement receivable, but the core company is still a small clinical-stage HBV developer that must prove imdusiran can move beyond Phase 2a signals.

Follow Add to Watchlist Ask Question

NASDAQ ABUS Coverage Bootstrap Biotechnology Chronic Hepatitis B RNAi

Latest ReportMay 13, 2026Arbutus (ABUS): the $179M settlement windfall hiding inside a pre-commercial HBV biotechView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.